Ozempic Gastroparesis Settlement: Criteria and Medical Context

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Targeted Risk Communication

For decades, public health communication has centered on general wellness and the broad dissemination of science-based information to empower individuals in managing their own health. This legacy framework has successfully guided millions toward preventive care, balanced nutrition, and awareness of common medical conditions. However, as pharmaceutical innovation accelerates, the same informational clarity must now extend to specific, real-world exposures that were not part of earlier public health dialogues. A clear example of this necessary pivot involves the transition from general health literacy to focused attention on medication-related risks. Patients who have been prescribed GLP-1 receptor agonists such as Ozempic for metabolic conditions now face emerging questions about potential gastrointestinal side effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying—has become a subject of heightened concern. The legal landscape has responded accordingly, with settlement criteria being developed for individuals who allege harm from prolonged exposure to this medication. This shift from broad health guidance to targeted exposure analysis requires a neutral, evidence-informed approach. The focus here is not on mechanistic claims but on the practical reality that patients and practitioners must navigate new risk-benefit calculations. Understanding the settlement criteria for Ozempic-related gastroparesis is now a critical component of informed decision-making, bridging the gap between general health awareness and specific pharmaceutical accountability.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and nutritional status. Ozempic (semaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). GLP-1 receptor agonists work by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. This pharmacologic effect on gastric motility is central to the mechanistic pathway linking Ozempic to gastroparesis. By delaying gastric emptying, Ozempic can exacerbate or unmask underlying gastroparesis, or in some cases, induce a condition that mimics it.

Clinical Trial Evidence of Gastrointestinal Adverse Reactions

Clinical trial data demonstrate a higher incidence of gastrointestinal adverse reactions among patients receiving Ozempic compared to placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients: 3.1% for the 0.5 mg dose and 3.8% for the 1 mg dose, compared to 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus the 1 mg dose (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions reported at frequencies below 5% include dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these are not specifically labeled as gastroparesis, they are consistent with the spectrum of symptoms associated with delayed gastric emptying.

Settlement Criteria for Ozempic-Associated Gastroparesis

The adequacy of warnings regarding Ozempic and gastroparesis is a key consideration in settlement-related discussions. The prescribing information for Ozempic does not explicitly list gastroparesis as a contraindication or warning. However, the drug's mechanism of action—slowing gastric emptying—is well-documented, and the high incidence of gastrointestinal adverse reactions is prominently noted. Patients who develop severe or persistent symptoms consistent with gastroparesis after starting Ozempic may argue that the risks were not adequately communicated. Settlement criteria for affected patients typically consider the following factors: a documented diagnosis of gastroparesis confirmed by gastric emptying scintigraphy or other objective measures; a clear temporal relationship between Ozempic initiation and symptom onset; the absence of other identifiable causes of gastroparesis, such as diabetes-related autonomic neuropathy, prior gastric surgery, or medication use; and the severity and duration of harm, including hospitalization, nutritional support, or permanent disability. The timeline between exposure and documented harm is critical. Symptoms often emerge during dose escalation, as noted in clinical trials where the majority of nausea, vomiting, and diarrhea occurred during this period (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, gastroparesis may develop more insidiously, with symptoms worsening over weeks to months. Patients who experience persistent gastrointestinal symptoms after dose stabilization or who require discontinuation of Ozempic due to intolerable effects may have stronger claims. Medical records should document the start date of Ozempic, dose changes, symptom onset, diagnostic testing, and any interventions such as antiemetics, prokinetic agents, or dietary modifications.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it diagnosed?

Gastroparesis is a disorder characterized by delayed gastric emptying without mechanical obstruction, causing symptoms like nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach.

What settlement criteria are considered for Ozempic-related gastroparesis claims?

Settlement criteria typically include a documented diagnosis of gastroparesis confirmed by objective measures, a clear temporal relationship between Ozempic initiation and symptom onset, absence of other identifiable causes, and severity of harm such as hospitalization or permanent disability. Medical records should document exposure, dose changes, and symptom progression.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.